Skip to main content
Premium Trial:

Request an Annual Quote

Warnex Licenses Xenomics' AML Dx Marker

NEW YORK (GenomeWeb News) – Warnex Medical Laboratories has licensed from Xenomics the rights to use a marker for acute myeloid leukemia in a diagnostic test, Xenomics said Thursday.

The agreement gives Warnex nonexclusive rights in Canada to use a recently discovered mutation in the NPM1 gene in a lab service to help doctors diagnose, stratify, and monitor AML patients.

The marker also could help doctors decide which patients are likely to benefit from intensive chemotherapy and those who are less likely to show positive responses to the treatment. The company said the mutation also may be used to monitor AML patients for residual disease during chemotherapy and to stratify patients involved in clinical trials.